Literature DB >> 12828496

Lower respiratory tract infections: impact on the workplace.

Howard Birnbaum1, Melissa Morley, Stephanie Leong, Paul Greenberg, Gene Colice.   

Abstract

BACKGROUND: While there is some literature on the cost of specific respiratory infections, much of the existing research focuses only on direct medical treatment costs and does not take into consideration workplace burden due to disability and absenteeism.
OBJECTIVE: To evaluate the impact of lower respiratory tract infections (LRTIs) on the workplace, specifically regarding the economic burden from an employer's perspective.
DESIGN: Specific LRTI considered here were acute bronchitis, acute exacerbations of chronic bronchitis and pneumonia. Data from medical, prescription drug and disability claims of a large, national company in the US were used. These data provide information on both the healthcare and work loss impacts of LRTI on this major self-insured employer. The annual per capita expenditures for persons with LRTI were determined for beneficiaries (including employees and dependants) of this employer by analysing all claims in 1997. Results were compared with those of a 10% random sample of beneficiaries in the employer's overall beneficiary population.
RESULTS: In 1997, total per person expenditures and total medical service utilisation were higher among beneficiaries with LRTI than among beneficiaries in the overall beneficiary population sample. Annual per capita employer expenditures for beneficiaries with LRTI totalled 6,116 US dollars, compared with 2,368 US dollars (1997 values) for the average beneficiary in the overall beneficiary population sample. Employer payments for lost work time through disability and absenteeism accounted for 17% of these expenditures amongst beneficiaries with LRTI and for 35% amongst employees with LRTI.
CONCLUSIONS: Annual per capita expenditures for beneficiaries with LRTI were almost three times that of the average beneficiary. We conclude that it is important to consider work loss in analyses of the cost of LRTI.

Entities:  

Mesh:

Year:  2003        PMID: 12828496     DOI: 10.2165/00019053-200321100-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  24 in total

Review 1.  The prevention of ventilator-associated pneumonia.

Authors:  M H Kollef
Journal:  N Engl J Med       Date:  1999-02-25       Impact factor: 91.245

2.  Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.

Authors:  J D Heffelfinger; S F Dowell; J H Jorgensen; K P Klugman; L R Mabry; D M Musher; J F Plouffe; A Rakowsky; A Schuchat; C G Whitney
Journal:  Arch Intern Med       Date:  2000-05-22

Review 3.  Cost-effective treatment of lower respiratory tract infections.

Authors:  J C Garrelts; A M Herrington
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

4.  Economic burden of pneumonia in an employed population.

Authors:  H G Birnbaum; M Morley; P E Greenberg; M Cifaldi; G L Colice
Journal:  Arch Intern Med       Date:  2001 Dec 10-24

5.  Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema.

Authors:  L Wilson; E B Devine; K So
Journal:  Respir Med       Date:  2000-03       Impact factor: 3.415

Review 6.  Infectious etiology of acute exacerbations of chronic bronchitis.

Authors:  S Sethi
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

7.  The costs of cancer to a major employer in the United States: a case-control analysis.

Authors:  A Barnett; H Birnbaum; P Y Cremieux; A M Fendrick; M Slavin
Journal:  Am J Manag Care       Date:  2000-11       Impact factor: 2.229

8.  Direct medical cost of chronic obstructive pulmonary disease in the U.S.A.

Authors:  M M Ward; H S Javitz; W M Smith; A Bakst
Journal:  Respir Med       Date:  2000-11       Impact factor: 3.415

9.  The burden of asthma and chronic obstructive pulmonary disease: data from The Netherlands.

Authors:  M P Rutten van-Mölken; T L Feenstra
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

10.  Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community.

Authors:  J T Macfarlane; A Colville; A Guion; R M Macfarlane; D H Rose
Journal:  Lancet       Date:  1993-02-27       Impact factor: 79.321

View more
  4 in total

Review 1.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Resource use and costs of treating acute cough/lower respiratory tract infections in 13 European countries: results and challenges.

Authors:  Raymond Oppong; Joanna Coast; Kerry Hood; Jacqui Nuttall; Richard D Smith; Christopher C Butler
Journal:  Eur J Health Econ       Date:  2010-04-03

3.  Use of ATP Readings to Predict a Successful Hygiene Intervention in the Workplace to Reduce the Spread of Viruses on Fomites.

Authors:  Laura Y Sifuentes; Sonia L M Fankem; Kelly Reynolds; Akrum H Tamimi; Charles P Gerba; David Koenig
Journal:  Food Environ Virol       Date:  2016-08-18       Impact factor: 2.778

Review 4.  Elements that contribute to healthy building design.

Authors:  Vivian Loftness; Bert Hakkinen; Olaf Adan; Aino Nevalainen
Journal:  Environ Health Perspect       Date:  2007-01-25       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.